LHA 510

Drug Profile

LHA 510

Alternative Names: LHA-510

Latest Information Update: 07 Nov 2016

Price : $50

At a glance

  • Originator Alcon
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 01 Oct 2016 Alcon completes a phase II trial in Wet Age-related macular degeneration in USA (Ophthalmic) (NCT02355028)
  • 04 Mar 2015 Phase-II clinical trials in Wet Age-related macular degeneration in USA (Ophthalmic) (NCT02355028)
  • 28 Jan 2015 Alcon plans a phase II trial for Age-related macular degeneration in USA (NCT02355028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top